Viral Core

LIke ThisLIke ThisLIke ThisLIke ThisLIke This

About us

The Boston Children’s Hospital Viral Core is located on the 13th floor of the Center for Life Science (CLS) building and provides technological resources to academic investigators interested in the development and use of viral based vectors. Currently, it offers custom lentiviral vector production, custom AAV vector production with a variety of serotypes and aliquots of in-stock vector.

The Viral Core operates under the direction of Dr. Zhigang He and is managed by Dr. Chen Wang with technical support staff.

Services and Pricing

Price:Internal/External academic/Corporate

AAV premade: 100ul-$200/$300/$400
custom made: 200ul~400ul-$600/$900/$1200
lenti custom made: 150ul-$400/$600/$800 

Policies

*Biosafety

It is Boston Children’s Hospital policy that all biological research including recombinant DNAs and viruses must be submitted to the Boston Children's Hospital Institutional Biosafety Committee (BCH IBC) for review and approval prior to initiation. Please provide documentation supporting that your project is approved. For questions regarding IBC registration, please contact: Despina Felis, Biosafety Officer, Phone 617-919-2288, Fax 617-730-0228, Email despina.felis@childrens.harvard.edu

* Small Scale viral prep test

For new viral vector, prior to large scale prep, we offer a service of small scale prep to confirm that the vector can be packaged without additional charge.

*Acknowledging the Core

Users are expected to acknowledge the Core in all publications that result from work supported by the Core.

Contact us

Zhigang He, PhD

F.M. Kirby Neurobiology Center
Boston Children’s Hospital
3 Blackfan Circle, CLS 13076
Boston MA 02115 USA
Tel 617-919-2353

zhigang.he@childrens.harvard.edu

Chen Wang, PhD

F.M. Kirby Neurobiology Center
Boston Children’s Hospital
3 Blackfan Circle, CLS 13060
Boston MA 02115 USA
Tel 617-919-2271

chen.wang@childrens.harvard.edu

The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”
- Sandra L. Fenwick, President and CEO
Close